Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Ina, Benoy"'
Autor:
Teboho Amelia Tiiti, Tebogo Loraine Mashishi, Varsetile Varster Nkwinika, Ina Benoy, Selokela Gloria Selabe, Johannes Bogers, Ramokone Lisbeth Lebelo
Publikováno v:
Virology Journal, Vol 18, Iss 1, Pp 1-9 (2021)
Abstract Background In 2017, the South African National Department of Health (NDoH) Cervical Cancer Prevention and Control Policy was revised. Human papillomavirus (HPV) testing on self-collected samples may offer improved screening uptake. The objec
Externí odkaz:
https://doaj.org/article/98c7552694a545d48ef1d67c77c10142
Autor:
Alex B. Mutombo, Ina Benoy, Rahma Tozin, Johannes Bogers, Jean-Pierre Van geertruyden, Yves Jacquemyn
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-9 (2019)
PURPOSE: Cervical cancer is the leading cause of mortality by cancer in sub-Saharan Africa. The human papillomavirus (HPV) infection is recognized as a necessary and sufficient cause for cervical cancer. Population-specific estimates of HPV prevalenc
Externí odkaz:
https://doaj.org/article/dbfec090a75c4582876ed10d762861bc
Publikováno v:
Contemporary Clinical Trials Communications, Vol 17, Iss , Pp - (2020)
Cutaneous warts comprise an extremely common condition caused by infection with the human papillomavirus (HPV). Although most verrucae will disappear spontaneously, many patients do seek treatment. Current wart treatments do not target the cause of t
Externí odkaz:
https://doaj.org/article/cc828b22061c47ce963df25c972966ba
Autor:
Neil H. Wood, Koketso S. Makua, Ramokone L. Lebelo, Nina Redzic, Ina Benoy, Olivier M. Vanderveken, Johannes Bogers
Publikováno v:
Advances in Virology, Vol 2020 (2020)
Introduction. Studies on HPV prevalence in the head and neck region of South Africans are sparse. Of the available reports in the literature, there were no studies on the association between HPV-DNA presence in the mouth and oropharynx in relation to
Externí odkaz:
https://doaj.org/article/c9dd3a1e140f4acca49f310f1ce519af
Publikováno v:
Virology Journal, Vol 15, Iss 1, Pp 1-5 (2018)
Abstract Background Cervical cancer screening with assays detecting DNA of high-risk human papillomavirus (hrHPV) types is more effective than cytology-based screening. This study completes the diagnostic accuracy assessment conducted previously with
Externí odkaz:
https://doaj.org/article/8d902d26e46f4b04a514b5cd01b30cf2
Autor:
Zacharie Ndizeye, Davy Vanden Broeck, Ramokone Lisbeth Lebelo, Johannes Bogers, Ina Benoy, Jean-Pierre Van Geertruyden
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0209303 (2019)
BackgroundHuman papillomaviruses are the most important causative agents for invasive cervical cancer development. HPV type-specific vaccination and HPV cervical cancer screening methods are being widely recommended to control the disease but the epi
Externí odkaz:
https://doaj.org/article/ad26a404ac604653b4e2dbc84a6562e8
Autor:
Marc Arbyn, Michael Pawlita, Jerome Antoine, Johannes Bogers, Ina Benoy, Christophe Depuydt, Markus Schmitt
PDF file - 44K, Supplementary Figure S1. HPV16 quantification by net MFI (A) or HPV16 to β-globin ratios (B) in HPV16 plasmid dilution series in 100 ng human placenta DNA per PCR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9265fa2336cb8ba0b277652abf77bf92
https://doi.org/10.1158/1055-9965.22437646
https://doi.org/10.1158/1055-9965.22437646
Autor:
Marc Arbyn, Michael Pawlita, Jerome Antoine, Johannes Bogers, Ina Benoy, Christophe Depuydt, Markus Schmitt
Background: Infections with high-risk human papillomaviruses (Hr-HPV) can cause malignant transformation of the human cervical epithelium. HPV DNA tests generally are very sensitive to detect cervical neoplastic lesions but also identify transient HP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ec580afeddc41596de552efb9f56a19
https://doi.org/10.1158/1055-9965.c.6515986
https://doi.org/10.1158/1055-9965.c.6515986
Publikováno v:
European journal of cancer prevention
OBJECTIVE In order to lower the incidence of cervical cancer, vaccines against high-risk types of the human papilloma virus (hrHPV) were approved and brought on the market in 2007, with a partial reimbursement for Belgian citizens younger than 18 yea